Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: A propensity score and <scp>B</scp> ayesian analysis

Objective In this study we aimed to compare patient outcomes between the use of transarterial radioembolization (TARE) and sorafenib in patients with hepatocellular carcinoma (HCC) intrahepatic portal vein tumor thrombosis (PVTT). Methods A total 65 HCC PVTT treated five Italian hospitals 2012 2018 were included analysis. Those any previous treatment, extension main tract extrahepatic involvement excluded. Propensity score matching analysis Bayesian model averaging performed. Results Of 41 TARE 24 sorafenib, 11 downstaged curative-intent surgery (liver transplant three hepatectomy eight), including 10 one sorafenib. was more effective than downstaging surgery, achieving a mean survival 54 months. without after whom 31 23 median 20.3 9.1 months, respectively (P = 0.001), different 1-, 2- 3-year OS rates (64.5%, 42.6% 37.3% vs 39.1%, 13.0% 0%). Both propensity confirmed an improvement overall group compared treatment. Conclusions providing significant survival. Even who not appeared be superior over